<DOC>
	<DOCNO>NCT00912743</DOCNO>
	<brief_summary>This study carry see new drug , olaparib ( AZD2281 ) , effectively safely treat advance large bowel cancer . The primary goal clinical trial determine whether olaparib beneficial effect patient 's cancer cause response increase time take cancer progress .</brief_summary>
	<brief_title>Efficacy Safety Olaparib Pretreated Patients With Measurable Colorectal Cancer , Stratified Microsatellite Instability ( MSI ) Status</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Microsatellite Instability</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Patients measurable disseminated colorectal cancer incurable surgery Patients tumor progression follow standard combination frontline secondline chemotherapy . CRC patient relapse recurrent disease within six month complete adjuvant neoadjuvant chemotherapy Previous treatment PARP inhibitor , include olaparib . Patients symptomatic , uncontrolled brain metastasis . Patients receive chemotherapy , radiotherapy ( except palliative reason ) , within 4 week last dose prior study entry ( long period depend defined characteristic agent use ) . Patients unable swallow orally administer medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Olaparib</keyword>
	<keyword>MSI status</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Measurable Colorectal Cancer</keyword>
	<keyword>Stratified MSI Status</keyword>
</DOC>